As of 2025-09-18, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 14.5x | 13.6x |
| Forward P/E multiples | 16.4x - 34.0x | 19.2x |
| Fair Price | (217.68) - (191.14) | (217.13) |
| Upside | -1068.8% - -950.6% | -1066.3% |
| Date | EV/EBITDA |